NASDAQ
92.38USD
+4.40 (+5.00%)
We have scored 22 news catalysts on Abivax S.A. (ABVX) over the past 12 months. The biggest single-day move next to one of them came Jun 3, 2026, when ABVX closed +24.3%: “Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)”. Coverage across the window leans positive (average ticker sentiment +0.18). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.8B
P/E
—
EPS
—
Beta
-0.25
52W range
69.81-148.83
Day range
88.03–92.78
Open
88.84
Prev close
87.98
Volume
1.5M
Avg volume
1.4M
Dividend
0.00
IPO
2023-10-20
Analysts publish price targets on ABVX, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
13 analyst price targets from $90 to $180
as of 2026-09-24
The market is 38% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Abivax S.A. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ABVX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
The reconstruction
The price at $92.38 sits at the 15th percentile of published models, endorsing the two hold-rated targets near $90 and rejecting the eleven bull targets up to $180, meaning the market has heavily discounted the drug's commercial potential relative to the analyst consensus.
What the disagreement turns on
Whether the malignancy risk ultimately limits obefazimod's patient population and commercial uptake, and the available wired data cannot settle this because drug prescription volumes and safety metrics are not measurable here.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
